+91-8668442535

Tuberculosis Treatment Market By Drug Class (First Line Treatment, Second Line Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on the global tuberculosis treatment market studies various drug classes. According to the World Health Organization (WHO), approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment. Its End T.B. Strategy aims to eradicate the global T.B. epidemic with a 95% reduction in T.B. deaths, cut new cases by 90% from 2015 to 2035, and ensure that patients are not burdened with huge expenses incurred due to T.B. The drivers of the tuberculosis treatment market are the rising prevalence of T.B. and MDR-TB, increasing public awareness regarding tuberculosis, and immediate enrollment of patients on the treatment regimen. The promising pipeline to overcome drug-induced resistance consists of bedaquiline, OPC-67683, PA-824, OFLOTUB, etc.

For the purpose of this study, the various drug classes of tuberculosis treatment studied include the first line of treatment, which is segmented as isoniazid, ethambutol, pyrazinamide, and rifampin. Ethionamide, Cycloserine, Para-amino-Salicylic Acid, and Kanamycin comprise the second line of treatment. The global tuberculosis treatment market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global tuberculosis treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global tuberculosis treatment market. The key players profiled in this report are Bayer Healthcare, Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc., and Sanofi S.A.

Based on drug class, the global tuberculosis treatment market is categorized into:

First-line treatment

  • Cytochrome P-450 Inhibitor (Isoniazid)
  • Mycolic acid inhibitor (Ethambutol)
  • FAS I inhibitor (pyrazinamide)
  • RNA polymerase inhibitor (Rifampin)

Second-line treatment

  • Mycolic acid inhibitor (Ethionamide)
  • Peptidoglycan inhibitor (Cycloserine)
  • Folic acid inhibitor (para-aminosalicylic acid)
  • 30S ribosomal inhibitor (kanamycin)

The United Nations adopted the Sustainable Development Goals (SDGs) in 2015, with eradicating tuberculosis as one of its major goals; similarly, the World Health Organization claims that its tuberculosis strategy will achieve a 90% reduction in tuberculosis deaths and an 80% reduction in T.B. incidence rate by 2030. The growing public awareness of tuberculosis and its treatment regimen, as well as its low cost, is driving the growth of the tuberculosis drug class segment. In 2016, first-line treatment held the largest market due to the increasing number of new cases of T.B., early T.B. screening resulting in a large turnout of patients on first-line treatment, and government initiatives such as DOTS at the primary health centers to bring under its ambit patients with unmet medical needs.

Second-line treatment will register faster growth throughout the forecast period of 2017–2025 due to factors such as the rising prevalence of MDR-TB (according to the World Health Organization, in 2015, there were 480,000 new reported cases), lack of patient compliance with the prescribed first-line treatment dosage regimen, and rising incidences of hospital-acquired infections. Overall, the tuberculosis drug market is highly competitive, with multiple players like Novartis AG, Bayer Healthcare, Labatec Pharma S.A., Mylan N.V., Otsuka Novel Products GmbH, etc., specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the technological advancement in drug formulation regarding the pharmacodynamics and pharmacokinetic aspects for better patient compliance and low cost.

For the purpose of this study, the global tuberculosis treatment market is categorized into:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

North America will be the fastest-growing market for tuberculosis treatment throughout the forecast period of 2017–2025. According to the Centers for Disease Control and Prevention, 9,421 TB cases were reported in 2014, i.e., a rate of 2.96 cases per 100,000 persons. The market growth is mainly attributed to the rising prevalence of tuberculosis, an evolving reimbursement scenario, and a developed healthcare infrastructure. According to the World Health Organization (WHO), in 2015, 32,000 patient deaths were reported in Europe. The growth of the tuberculosis treatment market is attributed to the prevalence of MDR-TB in eastern European countries and supportive regulatory approval for the tuberculosis treatment market. In the base year 2016, Asia Pacific was observed as the leading market for tuberculosis treatment due to factors such as the rising prevalence of tuberculosis, according to the World Health Organization.

South East Asia had 4.8 million prevalent cases and 450,000 deaths in 2012, creating a competitive market due to manufacturers involved in the production of tuberculosis treatment drugs, increasing disposable income in these regions, and government and non-government initiatives such as DOTS to mitigate tuberculosis. However, factors such as developing health infrastructure and increasing awareness about tuberculosis treatment are going to fuel the rapid growth of the tuberculosis treatment market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Questions:

The market for Tuberculosis Treatment Market is expected to reach US$ 1,306.6 Mn By 2025.

The Tuberculosis Treatment Market is expected to see significant CAGR growth over the coming years, at 4.9%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc., and Sanofi S.A. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58586
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support